Trial Profile
A Multicenter, Randomized, Evaluator Blinded, Active-Controlled Study to Evaluate the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2019
Price :
$35
*
At a glance
- Drugs Ibrexafungerp (Primary) ; Fluconazole
- Indications Vulvovaginal candidiasis
- Focus Proof of concept; Therapeutic Use
- Sponsors SCYNEXIS
- 14 Aug 2017 According to a Scynexis media release, results from this trial were presented at the 2017 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting.
- 08 Aug 2017 According to a Scynexis media release, results from this trial will be presented at the 2017 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting.
- 24 May 2017 Data from this trial will be presented at the ASM Microbe 2017, according to a SCYNEXIS media release.